Telomerase activity in plasma cell dyscrasias

被引:0
|
作者
D Xu
C Zheng
S Bergenbrant
G Holm
M Björkholm
Q Yi
A Gruber
机构
[1] Karolinska Hospital,Department of Medicine, Division of Hematology
[2] University of Arkansas for Medical Sciences,Myeloma and Transplantation Research Center
来源
British Journal of Cancer | 2001年 / 84卷
关键词
hTERT; multiple myeloma; plasma cells; telomerase;
D O I
暂无
中图分类号
学科分类号
摘要
Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investigated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and plasma cell leukaemia (PCL). All 5 patients with MGUS exhibited normal levels of telomerase activity in their plasma cells. Elevated telomerase activity was found in the samples from 21/27 patients with MM and 4/4 with PCL. In addition, 4 myeloma cell lines all expressed high levels of telomerase activity. The expression of telomerase reverse transcriptase (hTERT) and telomerase RNA template (hTER) was positively associated with the levels of telomerase activity in MM/PCL. Tankyrase expression was upregulated, concomitant with the induction of hTERT and activation of telomerase in MM/PCL. The present findings indicate that MGUS cells may not be immortalized and that activation of telomerase plays a role in the malignant transformation from MGUS to MM. © 2001 Cancer Research Campaign
引用
收藏
页码:621 / 625
页数:4
相关论文
共 50 条
  • [1] Telomerase activity in plasma cell dyscrasias
    Xu, D
    Zheng, C
    Bergenbrant, S
    Holm, G
    Björkholm, M
    Yi, Q
    Gruber, A
    BRITISH JOURNAL OF CANCER, 2001, 84 (05) : 621 - 625
  • [2] Telomerase activity in plasma cell dyscrasias.
    Gruber, A
    Zheng, CY
    Bergenbrant, S
    Holm, G
    Björkholm, M
    Yi, Q
    Xu, DW
    BLOOD, 2000, 96 (11) : 154A - 154A
  • [3] Plasma cell dyscrasias
    Nishimoto, N
    Suematsu, S
    Kishimoto, T
    ADVANCES IN IMMUNOLOGY, VOL 64, 1997, 64 : 219 - 281
  • [4] Plasma cell dyscrasias and amyloidosis
    Lebowitz, RA
    Morris, L
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2003, 36 (04) : 747 - +
  • [5] PLASMA-CELL DYSCRASIAS
    BUSS, DH
    PRICHARD, RW
    COOPER, MR
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1988, 2 (04) : 603 - 615
  • [6] Hyperviscosity in plasma cell dyscrasias
    Kwaan, Hau C.
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2013, 55 (01) : 75 - 83
  • [7] PLASMA-CELL DYSCRASIAS
    BARLOGIE, B
    ALEXANIAN, R
    JAGANNATH, S
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (20): : 2946 - 2951
  • [8] Elevated Nuclease Activity Correlates With Clinical Spectrum Of Plasma Cell Dyscrasias
    Patel, Jaymin M.
    Vahia, Ankit V.
    Nanjappa, Puru
    Bajwa, Ashun
    Shah, Sima
    Tai Yu-Tzu
    Anderson, Kenneth C.
    Shammas, Masood
    Munshi, Nikhil C.
    BLOOD, 2013, 122 (21)
  • [9] Treatment of plasma cell dyscrasias with lenalidomide
    Dimopoulos, M. A.
    Kastritis, E.
    Rajkumar, S. V.
    LEUKEMIA, 2008, 22 (07) : 1343 - 1353
  • [10] Anticipation in familial plasma cell dyscrasias
    Deshpande, HA
    Hu, XP
    Maring, P
    Jan, NA
    Wiernik, PH
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (03) : 696 - 703